Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I study of AER001 and AER002 in healthy volunteers
NL-OMON51340Phase 1Active, not recruiting
- Sponsor
- Aerium Therapeutics
- Start
- Aug 2022
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of AER001 and AER002 in coronavirus disease 2019 (COVID-19) (5 arms), sponsored by Aerium Therapeutics. Primary endpoint: Safety and tolerability of AER001 and AER002. Started Aug 2022; status: active, not recruiting.
02
Drugs
AER001AER002
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NL-OMON51340.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51340.